Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China.
Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, People's Republic of China.
EBioMedicine. 2021 Sep;71:103560. doi: 10.1016/j.ebiom.2021.103560. Epub 2021 Sep 2.
Recent evidence shows that inducing ferroptosis may improve efficacy of tumor therapy. However, ferroptosis-related genes have been little studied in patients with breast cancer especially in the neoadjuvant setting. ACSL4 and GPX4 have been well established as the positive and negative regulator of ferroptosis, respectively. This study aimed to explore the predictive value of ACSL4 and GPX4 for patients with breast cancer administered neoadjuvant chemotherapy.
This study included patients treated with paclitaxel-cisplatin-based neoadjuvant chemotherapy. Immunohistochemistry staining of ACSL4 and GPX4 was carried out on the core needle biopsy specimens. Logistic regression was performed to explore the predictive biomarkers of pathological complete response (pCR). Survival analyses were examined by log-rank test and Cox proportional hazard regression.
A total of 199 patients were included for the analyses. Both ACSL4 expression and ACSL4/GPX4 combination status could serve as independent predictive factors for pCR. The interaction for pCR was observed between ACSL4 and clinical tumor stage. Besides, ACSL4 expression, GPX4 expression, and their combination status were independent prognostic factors for disease-free survival. Analyses of the Kaplan-Meier Plotter database suggested that higher ACSL4 expression is related to better overall survival, and higher GPX4 expression is related to better distant metastasis-free survival. Pathway analyses revealed that ACSL4 and GPX4 might function in crucial pathways including apoptosis, autophagy, cell adhesion, lipid metabolism, etc. INTERPRETATION: This study revealed the critical value of ACSL4 and GPX4 serving as novel predictive and prognostic biomarkers for patients with breast cancer receiving neoadjuvant chemotherapy. It might be a novel strategy to induce ferroptosis to promote chemosensitivity. Future studies are required to elucidate the potential mechanisms.
This work was supported by Shanghai Natural Science Foundation [grant number 19ZR1431100], Clinical Research Plan of Shanghai Hospital Development Center [grant numbers SHDC2020CR3003A, 16CR3065B, and 12016231], Shanghai "Rising Stars of Medical Talent" Youth Development Program for Youth Medical Talents - Specialist Program [grant number 2018-15], Shanghai "Rising Stars of Medical Talent" Youth Development Program for Outstanding Youth Medical Talents [grant number 2018-16], Shanghai Collaborative Innovation Center for Translational Medicine [grant number TM201908], Multidisciplinary Cross Research Foundation of Shanghai Jiao Tong University [grant numbers YG2017QN49, ZH2018QNA42, and YG2019QNA28], Nurturing Fund of Renji Hospital [grant numbers PYMDT-002, PY2018-IIC-01, PY2018-III-15, and PYIII20-09], Science and Technology Commission of Shanghai Municipality [grant numbers 20DZ2201600 and 15JC1402700], and Shanghai Municipal Key Clinical Specialty.
最近的证据表明,诱导铁死亡可能会提高肿瘤治疗的疗效。然而,铁死亡相关基因在乳腺癌患者中,尤其是在新辅助治疗环境中,研究甚少。ACSL4 和 GPX4 已被很好地确立为铁死亡的阳性和阴性调节剂。本研究旨在探讨 ACSL4 和 GPX4 对接受新辅助化疗的乳腺癌患者的预测价值。
本研究纳入了接受紫杉醇-顺铂为基础的新辅助化疗的患者。对核心针活检标本进行 ACSL4 和 GPX4 的免疫组织化学染色。采用 logistic 回归分析探讨病理完全缓解(pCR)的预测生物标志物。通过对数秩检验和 Cox 比例风险回归分析进行生存分析。
共纳入 199 例患者进行分析。ACSL4 表达和 ACSL4/GPX4 联合状态均可作为 pCR 的独立预测因素。ACSL4 与临床肿瘤分期之间存在 pCR 的交互作用。此外,ACSL4 表达、GPX4 表达及其联合状态是无病生存的独立预后因素。Kaplan-Meier Plotter 数据库的分析表明,ACSL4 表达水平较高与总生存较好相关,GPX4 表达水平较高与远处无转移生存较好相关。通路分析表明,ACSL4 和 GPX4 可能在凋亡、自噬、细胞黏附、脂质代谢等关键通路中发挥作用。
本研究揭示了 ACSL4 和 GPX4 作为新的预测和预后生物标志物在接受新辅助化疗的乳腺癌患者中的重要价值。诱导铁死亡以提高化疗敏感性可能是一种新的策略。需要进一步的研究来阐明其潜在的机制。
本研究得到了上海市自然科学基金[项目编号 19ZR1431100]、上海市医院发展中心临床研究计划[项目编号 SHDC2020CR3003A、16CR3065B 和 12016231]、上海“医苑新星”青年医学人才培养资助计划(专科项目)[项目编号 2018-15]、上海“医苑新星”杰出青年医学人才培养资助计划[项目编号 2018-16]、上海交通大学转化医学协同创新中心[项目编号 TM201908]、上海交通大学多学科交叉研究基金[项目编号 YG2017QN49、ZH2018QNA42、YG2019QNA28]、仁济医院培育基金[项目编号 PYMDT-002、PY2018-IIC-01、PY2018-III-15 和 PYIII20-09]、上海市科学技术委员会[项目编号 20DZ2201600 和 15JC1402700]的支持。